Finalized Projects
AROMICS is an innovative company that from its very beginning is committed to the advancement of science. Aromics has participated as a partner in several European ( FP6, FP7, Era-net and Horizon 2020), national (CDTI, ICEX) and local (ACC1Ó) R&D projects.
METACAN aims to gaining understanding on how modulating cell metabolism may interfere with tumor growth focusing as well in terms of the interactions between cancer and immune cells. The knowledge acquired will serve as a platform for drug discovery and diagnostics efforts that aim to therapeutically target metabolism, inflammation or immune responses for the treatment of a variety of cancers.
(Co-financed by the Horizon 2020 Programme of the European Union)
AMMIC project focuses on the implementation of a drug discovery and development platform, from early stages up to clinical trials, to accelerate the discovery of medicines for rare disease (the so called orphan drugs). Other aspects like genomics, epigenomics, transcriptomics and liquid biopsies are also addressed inside the project, in order to improve as well the diagnosis and managment of rare diseases, with a particular focus on pediatric oncology conditions.
(Co-financed by FEDER programme)
ACCELEROMICS
This project, started on April 2011, aims to develop a novel antiviral for the treatment of Hepatitis C.
HILYSENS
The project aims to develop a novel lab-on-chip diagnostic tool to improve clinical diagnostic, disease monitoring and treatment of Lyme Disease by enabling specific and sensitive detection of the human serological response against its causative agent Borrelia burgdoferi infections.
MSALS
The aim of the project is to develop a novel treatment for Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). General objectives pursued by the project include: i) to conduct preclinical studies to assess the drug efficacy in an accepted animal model of ALS; (ii) to conduct a clinical trial in patients with Relapsing-Remitting MS to assess the efficacy and safety of the developed drug; and finally (III) the validation of genetic biomarkers of efficacy response of the proposed treatment in MS.
SMART
The final goal of the project is the experimental validation (proof of concept) of a new method for the treatment of infectious diseases specifically targeting bacterial thymidylate synthase (TS) by recently patented compounds
CLEANHIVE
The main objective of CLEANHIVE is to develop a portable, cost-effective, easy to use and sensitive tool able to detect both Nosema species involved in the depopulation syndrome, to be used in field conditions by non-technical staff in the beekeeping sector in order to stop the spread of Nosema ceranae.
AUTOSCREEN
This project, started on January 1st 2007, aims to develop an innovative screening platform suitable for high-throughput and high-content cell-based assays and to demonstrate its suitability for high-resolution in situ techniques.